Novarad, a leading developer of medical imaging software solutions, has announced an agreement with CureMetrix, Inc., a company that offers artificial intelligence (AI)-based solutions to the medical imaging community.

David Grandpre, Senior Director of Product at Novarad, said, “Our vision for transformative imaging technology aligns perfectly with the mission of CureMetrix to support and advance women’s health. By integrating these highly trained, proven algorithms with our existing mammography offerings, radiologists will be able to streamline their workflow, reduce false positives and enhance their ability to diagnose breast cancer earlier. That’s why we are excited to bring CureMetrix AI for mammography to Novarad customers and help save more lives.”

Novarad’s imaging capabilities will be provided nationwide in the United States and will be integrated with the CureMetrix AI-driven women’s health suite of tools for mammography. Novarad will be CureMetrix AI’s official PACS distributor for small and medium-sized imaging centers and hospitals.

Navid Alipour, Chief Executive Officer of CureMetrix, said, “By integrating our AI solutions with Novarad’s we can help radiologists diagnose breast cancer earlier and more accurately, and help doctors identify women at risk for CHD. CureMetrix solutions will enhance the performance of physicians using Novarad’s outstanding platforms, improving both clinical and financial outcomes both now and well into the future.”

Both the Journal of the American College of Radiology (JACR) and the Journal of Digital Imaging have published articles about the possible influence of CureMetrix AI breakthroughs in radiology (JDI). cmTriage®, an FDA-cleared application from CureMetrix, prioritizes worrisome cases and adds them to the radiology worklist. The mammography tests are then analyzed by cmAssist®, a sophisticated AI-based CAD algorithm that helps the radiologist locate, mark, and score problematic lesions. Then cmDensity™ classifies the patient’s breast density using the BIRADS Fifth Edition standards established by the American College of Radiology (ACR).

Novarad will also work with CureMetrix on the installation of new cmAngio™, AI-based software that uses a woman’s mammography to help clinicians assess her risk of coronary heart disease (CHD), the leading cause of death among women.